Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for Refractory Immune Cytopenias After Allo-HCT
NCT05873205Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in Refractory immune thrombocytopenia (RITP), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2023; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
Refractory immune thrombocytopenia (RITP)
Beyond the preview
Go deeper on NCT05873205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873205.